Zhejiang Jingxin Pharmaceutical Co., Ltd.

Zhejiang Jingxin Pharmaceutical Co., Ltd. (securities code: 002020) was founded in 1990 and is a pharmaceutical listed company integrating R&D, production and sales. It states a mission of "carefully safeguarding health" and aims to become a leader in China's neuropsychiatric and cardiovascular-cerebrovascular fields. Its pharmaceutical business is its core leading business, with treatments concentrated in three areas: neuropsychiatry, cardiovascular-cerebrovascular and digestive tract. Medical devices are its second-largest pillar business, with subsidiary Shenzhen Jufeng Display Technology Co., Ltd. As of June 30, 2026, the company had accumulated 240 patents, including 172 invention patents.

Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1990. It is a pharmaceutical listed company integrating R&D, production and sales, with securities code 002020. The company has two headquarters, in Xinchang and Hangzhou, and seven production bases: a formulation production base in Xinchang; API production bases in Shangyu and Weifang, Shandong; traditional Chinese medicine production bases in Bayannur, Inner Mongolia and Shaxi, Guangdong; and medical device production bases in Shenzhen and Shenyang. It has invested in and cooperatively established companies and R&D laboratories in countries including the United States, Israel and South Korea. Its solid formulation production line passed German GMP certification in 2006, and it passed a US FDA on-site inspection in 2018. As of June 30, 2026, the company had accumulated 240 patents, including 172 invention patents.

• 2025

  Class 1 innovative drug Jingnuoning (didaxini capsules) achieved sales of 195 million yuan; Jingchangle (bacillus licheniformis live bacteria capsules) instant retail digital intelligence marketing project launched; company established formulation business division; company launched AI intelligent agent planning and implementation project.

• 2018

  Passed U.S. FDA CGMP on-site inspection.

• 2006

  Solid preparation production line among the first to pass German GMP certification.

• 2004

  Included in the company's development timeline.

• 2001

  Listed on the Shenzhen Stock Exchange under stock code 002020.

• 1990

  Zhejiang Jingxin Pharmaceutical Co., Ltd. is founded.

Aiming to become a leader in China's neuropsychiatric and cardiovascular-cerebrovascular fields; pharmaceutical business is the core leading business, medical devices the second-largest pillar.

• Pharmaceuticals (chemical APIs, chemical formulations, Chinese patent medicines and biological preparations)

• APIs

• Intermediates

• Medical devices

• 2024

  Fined RMB 800,000 for underpaying tax due to improper R&D expense deductions

  In its Hong Kong IPO filing, Jingxin Pharmaceutical disclosed that in December 2024 it was fined RMB 800,000 by tax authorities for improper R&D expense deductions that underpaid corporate income tax by about RMB 1 million, and for failing to withhold and remit about RMB 400,000 in personal income tax in 2021 and 2023. Fine.

  Source

Read more

1. 1京新药业官网jingxinpharm.com
2. 2京新药业官网jingxinpharm.com
3. 3京新药业官网jingxinpharm.com
4. 4浙江京新药业股份有限公司wikidata.org
5. 5Fined RMB 800,000 for underpaying tax due to improper R&D expense deductionsmrjjxw.com
6. 6Fined RMB 800,000 for underpaying tax due to improper R&D expense deductionsbjnews.com.cn